169 related articles for article (PubMed ID: 23806325)
1. Asymmetric dimethylarginine serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
Genre F; López-Mejías R; Miranda-Filloy JA; Carnero-López B; Gómez-Acebo I; Blanco R; Ochoa R; Rueda J; González-Juanatey C; Llorca J; González-Gay MA
Clin Exp Rheumatol; 2013; 31(5):749-55. PubMed ID: 23806325
[TBL] [Abstract][Full Text] [Related]
2. Correlation between insulin resistance and serum ghrelin in non-diabetic ankylosing spondylitis patients undergoing anti-TNF-α therapy.
Genre F; López-Mejías R; Miranda-Filloy JA; Carnero-López B; Gómez-Acebo I; Blanco R; Ochoa R; Rueda J; González-Juanatey C; Llorca J; González-Gay MÁ
Clin Exp Rheumatol; 2013; 31(6):913-8. PubMed ID: 23981480
[TBL] [Abstract][Full Text] [Related]
3. Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
Genre F; López-Mejías R; Miranda-Filloy JA; Ubilla B; Carnero-López B; Palmou-Fontana N; Gómez-Acebo I; Blanco R; Rueda-Gotor J; Pina T; González-Juanatey C; Llorca J; González-Gay MÁ
Clin Exp Rheumatol; 2014; 32(5):640-6. PubMed ID: 25190453
[TBL] [Abstract][Full Text] [Related]
4. Apelin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
Genre F; Miranda-Filloy JA; López-Mejias R; Carnero-López B; Ochoa R; Rueda J; González-Juanatey C; Blanco R; Llorca J; González-Gay MA
Clin Exp Rheumatol; 2013; 31(4):532-7. PubMed ID: 23484462
[TBL] [Abstract][Full Text] [Related]
5. Gelsolin levels are decreased in ankylosing spondylitis patients undergoing anti-TNF-alpha therapy.
Genre F; López-Mejías R; Miranda-Filloy JA; Ubilla B; Carnero-López B; Gómez-Acebo I; Blanco R; Ochoa R; Rueda-Gotor J; González-Juanatey C; Llorca J; González-Gay MA
Clin Exp Rheumatol; 2014; 32(2):218-24. PubMed ID: 24351434
[TBL] [Abstract][Full Text] [Related]
6. Leptin and visfatin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
Miranda-Filloy JA; López-Mejias R; Genre F; Carnero-López B; Ochoa R; Diaz de Terán T; González-Juanatey C; Blanco R; Llorca J; González-Gay MA
Clin Exp Rheumatol; 2013; 31(4):538-45. PubMed ID: 23711190
[TBL] [Abstract][Full Text] [Related]
7. Correlation between two biomarkers of atherosclerosis, osteopontin and angiopoietin-2, in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
Genre F; López-Mejías R; Miranda-Filloy JA; Ubilla B; Carnero-López B; Gómez-Acebo I; Blanco R; Ochoa R; Arias-Bajo M; Rueda-Gotor J; Paz-Carreira J; González-Juanatey C; Llorca J; González-Gay MA
Clin Exp Rheumatol; 2014; 32(2):231-6. PubMed ID: 24295386
[TBL] [Abstract][Full Text] [Related]
8. Adiponectin and resistin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
Miranda-Filloy JA; López-Mejias R; Genre F; Carnero-López B; Ochoa R; Diaz de Terán T; González-Juanatey C; Blanco R; Llorca J; González-Gay MA
Clin Exp Rheumatol; 2013; 31(3):365-71. PubMed ID: 23294554
[TBL] [Abstract][Full Text] [Related]
9. TNF-alpha antagonist therapy improves insulin sensitivity in non-diabetic ankylosing spondylitis patients.
Miranda-Filloy JA; Llorca J; Carnero-López B; González-Juanatey C; Blanco R; González-Gay MA
Clin Exp Rheumatol; 2012; 30(6):850-5. PubMed ID: 22765845
[TBL] [Abstract][Full Text] [Related]
10. Assessment of serum asymmetric dimethylarginine levels and left ventricular diastolic function in patients with ankylosing spondylitis.
Inci U; Yildiz A; Batmaz I; Tekbas E
Int J Rheum Dis; 2017 Feb; 20(2):238-244. PubMed ID: 26012572
[TBL] [Abstract][Full Text] [Related]
11. IGF-1 and ADMA levels are inversely correlated in nondiabetic ankylosing spondylitis patients undergoing anti-TNF-alpha therapy.
Genre F; López-Mejías R; Rueda-Gotor J; Miranda-Filloy JA; Ubilla B; Villar-Bonet A; Carnero-López B; Gómez-Acebo I; Blanco R; Pina T; González-Juanatey C; Llorca J; González-Gay MA
Biomed Res Int; 2014; 2014():671061. PubMed ID: 25295265
[TBL] [Abstract][Full Text] [Related]
12. Anti-TNF-α therapy reduces endothelial cell activation in non-diabetic ankylosing spondylitis patients.
Genre F; López-Mejías R; Miranda-Filloy JA; Ubilla B; Mijares V; Carnero-López B; Gómez-Acebo I; Dierssen-Sotos T; Remuzgo-Martínez S; Blanco R; Pina T; González-Juanatey C; Llorca J; González-Gay MA
Rheumatol Int; 2015 Dec; 35(12):2069-78. PubMed ID: 26143161
[TBL] [Abstract][Full Text] [Related]
13. Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy.
Gonzalez-Gay MA; Vazquez-Rodriguez TR; Garcia-Unzueta MT; Berja A; Miranda-Filloy JA; de Matias JM; Gonzalez-Juanatey C; Llorca J
Clin Exp Rheumatol; 2010; 28(1):56-62. PubMed ID: 20346239
[TBL] [Abstract][Full Text] [Related]
14. Asymmetric dimethylarginine but not osteoprotegerin correlates with disease severity in patients with moderate-to-severe psoriasis undergoing anti-tumor necrosis factor-α therapy.
Pina T; Genre F; Lopez-Mejias R; Armesto S; Ubilla B; Mijares V; Dierssen-Sotos T; Corrales A; Gonzalez-Lopez MA; Gonzalez-Vela MC; Blanco R; Hernández JL; Llorca J; Gonzalez-Gay MA
J Dermatol; 2016 Apr; 43(4):389-94. PubMed ID: 26364678
[TBL] [Abstract][Full Text] [Related]
15. Patients with ankylosing spondylitis and low disease activity because of anti-TNF-alpha therapy have higher TRAIL levels than controls: a potential compensatory effect.
Genre F; López-Mejías R; Rueda-Gotor J; Miranda-Filloy JA; Ubilla B; Carnero-López B; Palmou-Fontana N; Gómez-Acebo I; Blanco R; Pina T; Ochoa R; González-Juanatey C; Llorca J; González-Gay MA
Mediators Inflamm; 2014; 2014():798060. PubMed ID: 24976690
[TBL] [Abstract][Full Text] [Related]
16. Disparate effects of anti-TNF-α therapies on measures of disease activity and mediators of endothelial damage in ankylosing spondylitis.
Korkosz M; Gąsowski J; Surdacki A; Leszczyński P; Pawlak-Buś K; Jeka S; Siedlar M; Grodzicki T
Pharmacol Rep; 2013; 65(4):891-7. PubMed ID: 24145083
[TBL] [Abstract][Full Text] [Related]
17. The L-arginine/asymmetric dimethylarginine ratio is improved by anti-tumor necrosis factor-α therapy in inflammatory arthropathies. Associations with aortic stiffness.
Angel K; Provan SA; Mowinckel P; Seljeflot I; Kvien TK; Atar D
Atherosclerosis; 2012 Nov; 225(1):160-5. PubMed ID: 23014354
[TBL] [Abstract][Full Text] [Related]
18. Increased levels of asymmetric dimethylarginine (ADMA) in patients with ankylosing spondylitis.
Sari I; Kebapcilar L; Alacacioglu A; Bilgir O; Yildiz Y; Taylan A; Yuksel A; Kozaci DL
Intern Med; 2009; 48(16):1363-8. PubMed ID: 19687580
[TBL] [Abstract][Full Text] [Related]
19. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
Gonnet-Gracia C; Barnetche T; Richez C; Blanco P; Dehais J; Schaeverbeke T
Clin Exp Rheumatol; 2008; 26(3):401-7. PubMed ID: 18578960
[TBL] [Abstract][Full Text] [Related]
20. Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-alpha blockade.
Syngle A; Vohra K; Sharma A; Kaur L
Clin Rheumatol; 2010 Jul; 29(7):763-70. PubMed ID: 20204669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
